Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors

被引：0
|
作者：
Abou Jokh Casas, E. [1 ]
Pombo Pasin, M. D. [1 ]
Pubul Nunez, V. [1 ]
Garrido Pumar, M. [1 ]
Blanco Freire, M. N. [1 ]
Cabezas, J. [1 ]
Cameselle, J. [1 ]
Berrios, M. [1 ]
Argibay, S. [1 ]
Ruibal Morell, A. [1 ]
机构：
[1] Complejo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0742
引用
收藏
页码：S597 / S598
页数：2
相关论文
共 50 条
  • [41] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
    Bello, P.
    Jimenez-Fonseca, P.
    Percovich, J. C.
    Anido Herranz, U.
    Gajate, P.
    Castellon, M.
    Estorch, M.
    Gonzalez, E.
    Field, C.
    Garcia Alonso, P.
    Carmona-Bayonas, A.
    Mitjavila, M.
    [J]. NEUROENDOCRINOLOGY, 2019, 108 : 198 - 198
  • [42] Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE
    Parghane, Rahul V.
    Basu, Sandip
    [J]. JOURNAL OF NUCLEAR CARDIOLOGY, 2020, 27 (01) : 340 - 341
  • [43] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
    Zandee, Wouter T.
    Brabander, Tessa
    Blazevic, Anela
    Minczeles, Noemie S.
    Feelders, Richard A.
    de Herder, Wouter W.
    Hofland, Johannes
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3665 - E3672
  • [44] Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE
    Marin, G.
    Vanderlinden, B.
    Wimana, Z.
    Guiot, T.
    Karfis, I.
    Flamen, P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S159 - S160
  • [45] Safety and response after peptide receptor radionuclide therapy with 177Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial
    Kudo, Atsushi
    Tateishi, Ukihide
    Yoshimura, Ryoichi
    Tsuchiya, Junichi
    Yokoyama, Kota
    Takano, Shoko
    Kobayashi, Noritoshi
    Utsunomiya, Daisuke
    Hata, Masaharu
    Ichikawa, Yasushi
    Tanabe, Minoru
    Hosono, Makoto
    Kinuya, Seigo
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (04) : 487 - 499
  • [46] 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis
    Satapathy, Swayamjeet
    Mittal, Bhagwant Rai
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (12) : 1195 - 1203
  • [47] Combined use of 177Lu-DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well-differentiated neuroendocrine tumors: A preclinical study
    Fu, Jingjing
    Qiu, Fan
    Stolniceanu, Cati Raluca
    Yu, Fei
    Zang, Shiming
    Xiang, Yili
    Huang, Yue
    Matovic, Milovan
    Stefanescu, Cipriana
    Tang, Qiyun
    Wang, Feng
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 (04)
  • [48] 177Lu-DOTATATE Retention and Radiation Protection Precautions for Patients Undergoing Inpatient and Outpatient Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumours
    Levart, D. L.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S732 - S733
  • [49] Comparison of commercial dosimetric software platforms in patients treated with 177Lu-DOTATATE for peptide receptor radionuclide therapy
    Mora-Ramirez, Erick
    Santoro, Lore
    Cassol, Emmanuelle
    Ocampo-Ramos, Juan C.
    Clayton, Naomi
    Kayal, Gunjan
    Chouaf, Soufiane
    Trauchessec, Dorian
    Pouget, Jean-Pierre
    Kotzki, Pierre-Olivier
    Deshayes, Emmanuel
    Bardies, Manuel
    [J]. MEDICAL PHYSICS, 2020, 47 (09) : 4602 - 4615
  • [50] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Yeokyeong Shin
    Bo Hyun Moon
    Baek-Yeol Ryoo
    Heung-Moon Chang
    Kyu-pyo Kim
    Yong Sang Hong
    Tae Won Kim
    Jin-Sook Ryu
    Yong-il Kim
    Changhoon Yoo
    [J]. Targeted Oncology, 2024, 19 : 41 - 49
12345